Janssen develops online platform “EU Disease Lens”
24.03.2015 18:43
In Europe alone, more than 100,000 people suffer from tuberculosis - a number that increases around World Tuberculosis Day on March 24th. makes the threat of the infectious disease clear. The research-based pharmaceutical company Janssen is now bringing together more facts and figures about tuberculosis and 14 other serious diseases from the 28 member states of the European Union on its new interactive platform “EU Disease Lens”.
Are available at http://www.diseaselens.com for example, epidemiological data such as patient numbers and prevalence rates. In addition, the user receives an overview of the most recent drug approvals in the 15 disease areas and an outlook on innovations currently in development. All information in this disease monitor comes from publicly available sources such as the World Health Organization (WHO) and the European Commission. The platform is published and constantly updated by the Janssen Health Policy Center, which promotes exchange with partners in the healthcare system through numerous initiatives.
“With this service platform, Janssen makes it possible to collect and access information from various sources at a glance thanks to many interactive graphics,” explains Beatrice Tardieu, director of the Janssen Health Policy Center. “Our goal is to make the facts better known to the public, because only with in-depth knowledge can patient care be improved.”
Janssen launched the online platform “EU Disease Lens” on World Tuberculosis Day because, as a partner of the global “Stop Tuberculosis” initiative, the company is using it to draw attention to the serious problem of the infectious disease, in particular the increase in the multi-resistant variant of tuberculosis.
In addition to tuberculosis, the platform contains information on the following diseases: hepatitis C, HIV, schizophrenia, depression, Alzheimer's, psoriasis, inflammatory bowel disease, Crohn's disease, multiple myeloma, mantle cell lymphoma as well as prostate cancer and chronic lymphocytic leukemia. All information below http://www.diseaselens.com The company emphasizes that they are used for further training and are not to be understood as therapy recommendations.